Neutralising antibody potency against SARS-CoV-2 wild-type and omicron BA.1 and BA.4/5 variants in patients with inflammatory bowel disease treated with infliximab and vedolizumab after three doses of COVID-19 vaccine (CLARITY IBD): an analysis of a prospective multicentre cohort study

BACKGROUND: Anti-TNF drugs, such as infliximab, are associated with attenuated antibody responses after SARS-CoV-2 vaccination. We aimed to determine how the anti-TNF drug infliximab and the anti-integrin drug vedolizumab affect vaccine-induced neutralising antibodies against highly transmissible om...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Zhigang, Le, Kaixing, Zhou, Xin, Alexander, James L, Lin, Simeng, Bewshea, Claire, Chanchlani, Neil, Nice, Rachel, McDonald, Timothy J, Lamb, Christopher A, Sebastian, Shaji, Kok, Klaartje, Lees, Charlie W, Hart, Ailsa L, Pollok, Richard C, Boyton, Rosemary J, Altmann, Daniel M, Pollock, Katrina M, Goodhand, James R, Kennedy, Nicholas A, Ahmad, Tariq, Powell, Nick
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Author(s). Published by Elsevier Ltd. 2023
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9757903/
https://www.ncbi.nlm.nih.gov/pubmed/36481043
http://dx.doi.org/10.1016/S2468-1253(22)00389-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9757903/
https://www.ncbi.nlm.nih.gov/pubmed/36481043
http://dx.doi.org/10.1016/S2468-1253(22)00389-2

Ejemplares similares